NCT07477600 cfMSC Stem Cell Therapy Targeting COPD
| NCT ID | NCT07477600 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Shenzhen Geno-Immune Medical Institute |
| Condition | Chronic Obstructive Pulmonary Disease (COPD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-03-10 |
| Primary Completion | 2029-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 30 participants in total. It began in 2026-03-10 with a primary completion date of 2029-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objectives are to evaluate the safety and efficacy of infusion of fully characterized clonally derived fetal mesenchymal stem cells (cfMSCs) for the control of severe symptoms associated with moderate to severe chronic obstructive pulmonary disease.
Eligibility Criteria
Inclusion Criteria: 1. Ability to understand the study protocol and the willingness to provide written informed consent; 2. Age 40-80 years old, male or female; 3. Diagnosed with moderate to severe COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (GOLD Ⅱ-Ⅳ). 4. Regular use of COPD conventional drugs for more than 3 months, and the condition is stable for more than 4 weeks; 5. ineffective clinical treatment; 6. Life expectancy \> 6 months; 7. At least six months smoking cessation, including non-smoking during the treatment and follow-up periods of the study. Exclusion Criteria: 1. Combined with other serious lung diseases: asthma, active pulmonary tuberculosis, bronchiectasis, pulmonary embolism, interstitial lung disease, pulmonary hypertension, etc.; 2. A history of lung surgery (pneumonectomy, lung volume reduction surgery, etc.) or bronchial intervention surgery within 12 months; 3. Invasive or non-invasive mechanical ventilation history within 4 weeks, or moderate to severe acute exacerbation of COPD within 4 weeks; 4. Negative for HIV, HCV or syphilis serology; 5. A history of malignant tumors or malignant tumors under treatment; 6. Autoimmune diseases requiring long-term use of glucocorticoids or immunosuppressants; 7. Poorly controlled diabetes (fasting blood glucose \> 10.0 mmol/L) or severe metabolic diseases; 8. A history of alcohol or drug abuse, or mental diseases that cannot cooperate with the study; 9. Pregnancy or breastfeeding. 10. Unable or unwilling to comply with study specific schedules or procedures.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07477600 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 80 Years, studying Chronic Obstructive Pulmonary Disease (COPD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07477600 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07477600 currently recruiting?
Yes, NCT07477600 is actively recruiting participants. Contact the research team at c@szgimi.org for enrollment information.
Where is the NCT07477600 trial being conducted?
This trial is being conducted at Shenzhen, China.
Who is sponsoring the NCT07477600 clinical trial?
NCT07477600 is sponsored by Shenzhen Geno-Immune Medical Institute. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.